Market Closed -
Hong Kong S.E.
04:08:10 2024-05-21 am EDT
|
5-day change
|
1st Jan Change
|
38.65
HKD
|
-4.57%
|
|
-2.89%
|
-51.35%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
149,934
|
326,828
|
347,115
|
236,612
|
215,748
|
124,275
|
-
|
-
|
Enterprise Value (EV)
1 |
147,283
|
319,817
|
342,141
|
233,509
|
206,634
|
114,227
|
108,460
|
101,826
|
P/E ratio
|
82.2
x
|
108
x
|
68.5
x
|
28.7
x
|
22.5
x
|
13.3
x
|
11.1
x
|
10.4
x
|
Yield
|
0.37%
|
0.27%
|
0.44%
|
1.1%
|
1.35%
|
2.3%
|
2.44%
|
2.57%
|
Capitalization / Revenue
|
11.6
x
|
19.8
x
|
15.2
x
|
6.01
x
|
5.35
x
|
3.19
x
|
2.81
x
|
2.51
x
|
EV / Revenue
|
11.4
x
|
19.3
x
|
14.9
x
|
5.93
x
|
5.12
x
|
2.93
x
|
2.45
x
|
2.06
x
|
EV / EBITDA
|
42.7
x
|
73.6
x
|
46.8
x
|
18.9
x
|
14.6
x
|
8.18
x
|
6.82
x
|
6.12
x
|
EV / FCF
|
566
x
|
336
x
|
-146
x
|
246
x
|
26.2
x
|
15.7
x
|
12.3
x
|
5.68
x
|
FCF Yield
|
0.18%
|
0.3%
|
-0.69%
|
0.41%
|
3.82%
|
6.36%
|
8.13%
|
17.6%
|
Price to Book
|
8.79
x
|
10.1
x
|
9.11
x
|
5.15
x
|
3.92
x
|
2.07
x
|
1.78
x
|
1.6
x
|
Nbr of stocks (in thousands)
|
2,752,159
|
2,930,032
|
2,955,700
|
2,960,507
|
2,968,761
|
2,912,956
|
-
|
-
|
Reference price
2 |
54.83
|
112.3
|
118.6
|
81.00
|
72.76
|
43.71
|
43.71
|
43.71
|
Announcement Date
|
3/24/20
|
3/5/21
|
2/15/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
12,872
|
16,535
|
22,902
|
39,355
|
40,341
|
39,000
|
44,229
|
49,445
|
EBITDA
1 |
3,449
|
4,348
|
7,308
|
12,370
|
14,194
|
13,967
|
15,911
|
16,639
|
EBIT
1 |
2,486
|
3,656
|
6,038
|
10,652
|
11,872
|
11,298
|
12,807
|
13,388
|
Operating Margin
|
19.31%
|
22.11%
|
26.36%
|
27.07%
|
29.43%
|
28.97%
|
28.96%
|
27.08%
|
Earnings before Tax (EBT)
1 |
2,337
|
3,369
|
6,016
|
10,618
|
11,832
|
11,736
|
13,974
|
14,041
|
Net income
1 |
1,855
|
2,960
|
5,097
|
8,814
|
10,690
|
9,700
|
11,082
|
11,679
|
Net margin
|
14.41%
|
17.9%
|
22.26%
|
22.4%
|
26.5%
|
24.87%
|
25.06%
|
23.62%
|
EPS
2 |
0.6667
|
1.042
|
1.730
|
2.820
|
3.240
|
3.293
|
3.939
|
4.220
|
Free Cash Flow
1 |
260.3
|
951.3
|
-2,345
|
948
|
7,886
|
7,270
|
8,817
|
17,939
|
FCF margin
|
2.02%
|
5.75%
|
-10.24%
|
2.41%
|
19.55%
|
18.64%
|
19.94%
|
36.28%
|
FCF Conversion (EBITDA)
|
7.55%
|
21.88%
|
-
|
7.66%
|
55.56%
|
52.05%
|
55.41%
|
107.82%
|
FCF Conversion (Net income)
|
14.03%
|
32.14%
|
-
|
10.76%
|
73.77%
|
74.96%
|
79.56%
|
153.61%
|
Dividend per Share
2 |
0.2006
|
0.3025
|
0.5174
|
0.8927
|
0.9834
|
1.007
|
1.068
|
1.122
|
Announcement Date
|
3/24/20
|
3/5/21
|
2/15/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S2
|
2021 S1
|
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
6,978
|
9,304
|
10,537
|
6,381
|
21,849
|
8,474
|
-
|
17,756
|
10,638
|
10,960
|
21,598
|
8,964
|
9,908
|
18,871
|
10,670
|
10,799
|
21,470
|
7,982
|
9,304
|
17,286
|
10,161
|
12,621
|
22,781
|
9,920
|
10,964
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
1,725
|
2,955
|
1,522
|
3,142
|
2,224
|
2,978
|
5,202
|
2,728
|
3,453
|
6,181
|
-
|
3,797
|
6,412
|
3,395
|
2,065
|
6,877
|
2,325
|
2,809
|
4,718
|
2,774
|
3,545
|
6,319
|
-
|
-
|
Operating Margin
|
-
|
18.54%
|
28.04%
|
23.85%
|
14.38%
|
26.24%
|
-
|
29.29%
|
25.65%
|
31.51%
|
28.62%
|
-
|
38.33%
|
33.98%
|
31.82%
|
19.12%
|
32.03%
|
29.13%
|
30.19%
|
27.3%
|
27.3%
|
28.09%
|
27.74%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
1,447
|
-
|
5,587
|
-
|
1,999
|
-
|
-
|
-
|
1,799
|
5,078
|
2,609
|
3,786
|
6,395
|
3,387
|
2,050
|
6,534
|
2,297
|
2,928
|
-
|
3,285
|
3,670
|
-
|
-
|
-
|
Net income
1 |
-
|
1,243
|
-
|
1,535
|
4,830
|
1,643
|
2,993
|
-
|
2,742
|
1,436
|
4,178
|
2,168
|
3,145
|
5,313
|
2,763
|
2,614
|
5,377
|
1,942
|
2,396
|
-
|
2,716
|
3,012
|
-
|
-
|
-
|
Net margin
|
-
|
13.36%
|
-
|
24.05%
|
22.1%
|
19.39%
|
-
|
-
|
25.78%
|
13.1%
|
19.34%
|
24.19%
|
31.74%
|
28.15%
|
25.9%
|
24.2%
|
25.05%
|
24.33%
|
25.75%
|
-
|
26.73%
|
23.87%
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
0.5200
|
-
|
0.5300
|
0.9500
|
-
|
0.8200
|
0.5200
|
-
|
0.7200
|
1.070
|
-
|
0.9400
|
0.5100
|
-
|
0.6600
|
0.9100
|
-
|
0.8600
|
1.070
|
-
|
0.7000
|
1.210
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/20
|
3/5/21
|
8/12/21
|
2/15/22
|
2/15/22
|
4/25/22
|
7/26/22
|
7/26/22
|
10/26/22
|
3/20/23
|
3/20/23
|
4/24/23
|
7/31/23
|
7/31/23
|
10/30/23
|
3/18/24
|
3/18/24
|
4/29/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
638
|
7,011
|
4,974
|
3,103
|
9,115
|
10,048
|
15,814
|
22,449
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
260
|
951
|
-2,345
|
948
|
7,886
|
7,270
|
8,817
|
17,939
|
ROE (net income / shareholders' equity)
|
10.6%
|
11.9%
|
14.4%
|
20.6%
|
19%
|
16.8%
|
16.3%
|
15.5%
|
ROA (Net income/ Total Assets)
|
7.15%
|
7.84%
|
10.1%
|
15.2%
|
15.5%
|
12.6%
|
12.7%
|
12.6%
|
Assets
1 |
25,952
|
37,763
|
50,709
|
57,966
|
69,180
|
77,171
|
87,507
|
92,927
|
Book Value Per Share
2 |
6.240
|
11.10
|
13.00
|
15.70
|
18.60
|
21.20
|
24.50
|
27.30
|
Cash Flow per Share
2 |
1.050
|
1.360
|
1.560
|
3.590
|
4.510
|
4.350
|
4.670
|
5.240
|
Capex
1 |
2,269
|
3,022
|
6,934
|
9,668
|
5,500
|
5,720
|
5,436
|
4,996
|
Capex / Sales
|
17.63%
|
18.28%
|
30.28%
|
24.57%
|
13.63%
|
14.67%
|
12.29%
|
10.1%
|
Announcement Date
|
3/24/20
|
3/5/21
|
2/15/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
43.71
CNY Average target price
68.82
CNY Spread / Average Target +57.45% Consensus |
1st Jan change
|
Capi.
|
---|
| +8.63% | 115B | | +13.17% | 107B | | -12.76% | 22.31B | | -3.99% | 21.6B | | -7.19% | 18.23B | | +6.67% | 14.26B | | +33.90% | 12.37B | | -28.60% | 8.28B | | +17.28% | 8.26B |
Bio Therapeutic Drugs
|